Hepion pharmaceuticals further strengthens board with appointments of accomplished biopharmaceutical executives, mr. anand reddi and dr. kaouthar lbiati

Edison, n.j., june 28, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical mid-stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and hepatocellular carcinoma (“hcc”), today announced the appointments of anand reddi, m.s., and kaouthar lbiati, m.d., to its board of directors, effective immediately.
HEPA Ratings Summary
HEPA Quant Ranking